BeOne Medicines Presents New Data for Investigational Oncology Medicines at ESMO 2026

BeOne Medicines Ltd. presented new data at the ESMO Congress 2026, showcasing advancements in oncology, particularly in gastrointestinal, lung, and breast cancers. Notably, a potential first-in-class GPC3 x 4-1BB bispecific demonstrated a 36% confirmed response rate in heavily pretreated liver cancer. The company also reported durable survival benefits from the combination of TEVIMBRA and ZIIHERA for treating HER2-positive gastroesophageal adenocarcinoma.